IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

IMMUNEONCO-B (01541) announced that the Phase II clinical trial of IMM2510 (Perwittafusp Alfa) combined with IMM27M (Tislelizumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) has successfully completed the first patient dosing. The study aims to evaluate the preliminary efficacy and safety of the combination of IMM2510 and IMM27M in this patient population. Since the initial submission of the Investigational New Drug (IND) application for the combination of IMM2510 and IMM27M in 2023, the clinical development of this combination therapy has been progressing steadily and demonstrating exceptional potential. The Phase Ib clinical trial of IMM2510 combined with IMM27M for treating advanced solid tumors has determined the recommended Phase II dose (RP2D) and is currently conducting an expansion study in solid tumors following previous immunotherapy failure, including esophageal squamous carcinoma and squamous non-small cell lung cancer. Preliminary data indicate that the overall tolerability of this combination therapy is good. Among six patients with esophageal squamous carcinoma in the dose escalation phase who were evaluable for efficacy, three achieved partial response (PR), two had stable disease (SD), and one had immune system unconfirmed disease progression (iUPD), resulting in an objective response rate (ORR) of 50%. Encouraging early clinical results confirm that the combination of IMM2510 and IMM27M exhibits significant anti-tumor activity and controllable safety in the treatment of advanced solid tumors.